A report designed to help advocates understand results of the 2010 CAPRISA 004 trial and how they related to the research agenda for ARV-based prevention strategies.
A Cascade of Hope and Questions: Anticipating results of ARV-based HIV prevention trials
Understanding the Results of CAPRISA 004
A 2010 document discussing the results of the CAPRISA 004 microbicide gel trial. It explores the implications of the data and outlines the next steps in evaluating tenofovir gel.
PrEP: A new option for women for safer loving
A brochure designed for women who want information on whether PrEP is the right prevention option for them.
Adherence in HIV Prevention Research: A primer for HIV prevention advocates
A two-page resource providing simple explanations of how adherence is defined and measured in biomedical HIV prevention trials, with a focus on PrEP and microbicides.
Intermittent PrEP (iPrEP) Research Agenda: Summary of an amfAR/AVAC think tank
A six-page summary of a meeting convened by amfAR and AVAC involving leaders from research and research sponsor agencies. The meeting reviewed the status of biomedical, behavioral and animal research relevant to intermittent PrEP, identifed gaps and priorities for moving forward.
Next steps for PrEP: Getting a proven prevention option to the people who need it
An article from the June 2013 edition of the GMHC newsletter discussing issues of PrEP introduction worldwide, reviewing efficacy trial results and current status of regulatory approval of Truvada as PrEP and rollout efforts.
Women and Prevention Research: Designing, testing and marketing products to improve adherence
From AVAC’s Research & Reality webinar series, this recent webinar focused on essential questions about what recent trials do—and do not—tell us about whether women will want or use prevention tools including microbicide gels, rings and oral tenofovir-based PrEP.
Selected Trials of Long-Acting Injectables for Prevention and/or Treatment U=U of HIV
This Px Wire graphic from April-June 2014 Volume 7 No. 2 identifies selected trials of long-acting injectables in development for prevention and/or Treatment U=U of HIV.
A Three-Part Agenda for Ending AIDS 2014
The Px Wire centerspread from January-March Volume 7, No. 1 lays out the “research-to-rollout” continuum of steps between initial evaluations of a novel concept for HIV prevention and the ultimate introduction of new tool offered in an effective public health program.